Clear Street sees buying opportunity for Beam Therapeutics after study update

Clear Street analyst Bill Maughan maintains a Buy rating and $37 price target on shares of Beam Therapeutics (BEAM) after the company reported Phase 1/2 data for BEAM-302 in Alpha-1 Antitrypsin Deficiency that confirmed the optimal dose for pivotal development starting in 2H26. The update appears more de-risking than the muted market reaction suggests, supporting a constructive view and potential buying opportunity, the analyst tells investors in a research note.